MCD
MCID: MLT113
MIFTS: 50

Multicentric Castleman Disease (MCD)

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Multicentric Castleman Disease

MalaCards integrated aliases for Multicentric Castleman Disease:

Name: Multicentric Castleman Disease 12 53 15
Plasmablastic Multicentric Castleman Disease 12 53
Multicentric Giant Lymph Node Hyperplasia 12 53
Multi-Centric Castleman's Disease 44 73
Pmcd 12 53
Mcd 12 53
Multicentric Plasma Cell Variant of Castleman's Disease 53
Idiopathic Multicentric Castleman's Disease 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0111152
MeSH 44 C537372
NCIt 50 C27855
UMLS 73 C1334815

Summaries for Multicentric Castleman Disease

NIH Rare Diseases : 53 Multicentric Castleman disease (MCD) is a rare disease that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and involves multiple regions of lymph nodes (as opposed to unicentric Castleman disease, which involves a single lymph node or single region of lymph nodes). The signs and symptoms of MCD are often nonspecific, and are mild in some people but life-threatening in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. The disease is diagnosed based on the symptoms present, laboratory test results, imaging studies, and results of a biopsy of the lymph nodes which shows specific features when studied under the microscope. In some cases, MCD is caused by human herpesvirus-8 (HHV-8) and is referred to as HHV-8-associated MCD. In other cases, the cause is not known and it is referred to as HHV-8 negative MCD, or idiopathic MCD (iMCD). Treatment of MCD is challenging, and treatment options and outcomes depend on the type and severity in each person.

MalaCards based summary : Multicentric Castleman Disease, also known as plasmablastic multicentric castleman disease, is related to human herpesvirus 8 and castleman disease, and has symptoms including fever An important gene associated with Multicentric Castleman Disease is IL6 (Interleukin 6), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Ganciclovir and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A Castleman disease characterized by systemic inflammatory symptoms, polyclonal lymphoproliferation, cytopenias, and multiple organ system dysfunction caused by a cytokine storm often including interleukin-6.

Related Diseases for Multicentric Castleman Disease

Diseases related to Multicentric Castleman Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 human herpesvirus 8 32.8 BCL6 IL6
2 castleman disease 31.8 BCL6 CRP IL10 IL5 IL6 KRT15
3 primary effusion lymphoma 30.6 BCL6 IL6
4 hematopoietic stem cell transplantation 30.1 IL10 IL6
5 purpura 29.9 CRP F3 IL6
6 pneumonia 29.7 CRP IL10 IL5 IL6
7 lymphoma, non-hodgkin, familial 29.6 ABCB1 BCL6 PAX5
8 systemic lupus erythematosus 29.2 CRP F3 IL10 IL21 IL6
9 kaposi sarcoma 12.2
10 malonyl-coa decarboxylase deficiency 12.0
11 macular dystrophy, corneal 11.9
12 multiple carboxylase deficiency 11.9
13 metaphyseal chondrodysplasia, schmid type 11.8
14 holocarboxylase synthetase deficiency 11.8
15 biotinidase deficiency 11.7
16 focal segmental glomerulosclerosis 11.5
17 lipoid nephrosis 11.5
18 unicentric castleman disease 11.3
19 c1q nephropathy 11.1
20 corneal dystrophy, meesmann 11.0
21 metaphyseal dysplasia, spahr type 11.0
22 cortical malformations, occipital 11.0
23 microlissencephaly 11.0
24 sarcoma 10.6
25 lymphoma 10.3
26 cold agglutinin disease 10.3 CRP IL6
27 cryopyrin-associated periodic syndrome 10.3 CRP IL6
28 acute cholangitis 10.3 CRP IL6
29 uremic pruritus 10.2 CRP IL6
30 neutrophilia, hereditary 10.2 CRP IL6
31 eye lymphoma 10.2 IL10 IL6
32 spinal disease 10.2 CRP IL6
33 acute transverse myelitis 10.2 IL10 IL6
34 viral pneumonia 10.2 CRP IL6
35 transverse myelitis 10.2 IL10 IL6
36 relapsing polychondritis 10.2 CRP IL6
37 central nervous system vasculitis 10.2 CRP IL6
38 tafro syndrome 10.2
39 subacute thyroiditis 10.2 CRP IL6
40 funisitis 10.2 IL10 IL6
41 intussusception 10.2 CRP IL6
42 louse-borne relapsing fever 10.2 CRP IL6
43 cecal disease 10.2 CRP IL6
44 autoimmune gastritis 10.2 IL10 IL6
45 pyelitis 10.2 CRP IL6
46 ischemic heart disease 10.2 CRP IL6
47 viral meningitis 10.2 CRP IL6
48 cystic echinococcosis 10.2 IL10 IL6
49 hypersensitivity reaction type iii disease 10.2 CRP IL6
50 autoimmune disease of eyes, ear, nose and throat 10.2 IL10 IL6

Graphical network of the top 20 diseases related to Multicentric Castleman Disease:



Diseases related to Multicentric Castleman Disease

Symptoms & Phenotypes for Multicentric Castleman Disease

UMLS symptoms related to Multicentric Castleman Disease:


fever

MGI Mouse Phenotypes related to Multicentric Castleman Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ABCB1 BCL6 F3 IL10 IL21 IL5
2 homeostasis/metabolism MP:0005376 9.97 ABCB1 BCL6 CRP F3 IL10 IL21
3 immune system MP:0005387 9.91 ABCB1 BCL6 CRP F3 IL10 IL21
4 digestive/alimentary MP:0005381 9.8 ABCB1 IL10 IL5 IL6 KRT15
5 liver/biliary system MP:0005370 9.55 ABCB1 BCL6 IL10 IL5 IL6
6 neoplasm MP:0002006 9.35 F3 IL10 IL5 IL6 PAX5
7 respiratory system MP:0005388 9.02 BCL6 F3 IL10 IL5 IL6

Drugs & Therapeutics for Multicentric Castleman Disease

Drugs for Multicentric Castleman Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganciclovir Approved, Investigational Phase 4,Phase 2 82410-32-0 3454
2
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
3 Anti-Infective Agents Phase 4,Phase 2,Phase 1
4 Ganciclovir triphosphate Phase 4,Phase 2
5 Antiviral Agents Phase 4,Phase 2
6 Siltuximab Approved, Investigational Phase 2,Phase 1,Early Phase 1 541502-14-1
7
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
8
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
9
Zidovudine Approved Phase 2 30516-87-1 35370
10
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
11
Lenograstim Approved, Investigational Phase 2 135968-09-1
12
Everolimus Approved Phase 2 159351-69-6 6442177
13
Vincristine Approved, Investigational Phase 2,Phase 1 57-22-7, 2068-78-2 5978
14
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
15
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
16
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
17
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19 Pomalidomide Approved Phase 1, Phase 2 19171-19-8
20
Doxil Approved June 1999 Phase 2,Phase 1 31703
21 Antibodies, Monoclonal Phase 2,Phase 1,Early Phase 1
22 Antibodies Phase 2,Phase 1,Early Phase 1
23 Analgesics Phase 2
24 Immunologic Factors Phase 2,Phase 1,Early Phase 1
25 Antipyretics Phase 2
26 Histamine H1 Antagonists Phase 2
27 Immunoglobulins Phase 2,Phase 1,Early Phase 1
28 Histamine Antagonists Phase 2
29 Pharmaceutical Solutions Phase 2
30 Hormone Antagonists Phase 2,Phase 1
31 Antineoplastic Agents, Alkylating Phase 2,Phase 1
32 Alkylating Agents Phase 2,Phase 1
33 Antineoplastic Agents, Hormonal Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 2,Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
36 Anti-Inflammatory Agents Phase 2,Phase 1
37 Immunosuppressive Agents Phase 2,Phase 1
38 Antirheumatic Agents Phase 2,Phase 1
39 glucocorticoids Phase 2,Phase 1
40 Angiogenesis Inhibitors Phase 2,Phase 1
41 Angiogenesis Modulating Agents Phase 2,Phase 1
42 Hormones Phase 2,Phase 1
43 Reverse Transcriptase Inhibitors Phase 2
44 Anti-HIV Agents Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 2
46 Anti-Retroviral Agents Phase 2
47 Antimetabolites Phase 2
48 Antifungal Agents Phase 2
49 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
50 Etoposide phosphate Phase 2,Phase 1

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Withdrawn NCT00361933 Phase 4 Valganciclovir
2 A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease Completed NCT01024036 Phase 2 Siltuximab;Placebo;Best Supportive Care (BSC)
3 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease Completed NCT01400503 Phase 2 Siltuximab
4 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
5 TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial Recruiting NCT03043105 Phase 2 Thalidomide, cyclophosphamide and prednisone
6 Tocilizumab for KSHV-Associated Multicentric Castleman Disease Recruiting NCT01441063 Phase 2 Zidovudine;Tocilizumab;Valganciclovir (VGC)
7 Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity Recruiting NCT00092222 Phase 2 Etoposide;Interferon-alpha;Rituximab;Zidovudine;Liposomal Doxorubicin;Bortezomib;Valganciclovir;Doxorubicin;Vincristine;Cyclophosphamide;Filgrastim (G-CSF);Prednisone;Sirolimus
8 Siltuximab in Schizophrenia Recruiting NCT02796859 Phase 1, Phase 2 Siltuximab;normal saline
9 Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy Terminated NCT00127569 Phase 2 Rituximab
10 Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Withdrawn NCT02228512 Phase 1, Phase 2 Pomalidomide;Rituximab;Prednisone;Etoposide;Doxorubicin;Vincristine;Cyclophosphamide
11 A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed NCT01183598 Phase 1 tocilizumab [RoActemra/Actemra]
12 Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma Recruiting NCT02659930 Phase 1 liposomal doxorubicin;pomalidomide
13 Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Terminated NCT02109224 Phase 1 Ibrutinib
14 Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials Completed NCT00695422
15 Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease Recruiting NCT03300830
16 Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer Recruiting NCT00006518
17 Unlock the Cell: Castleman's Disease Flow Cytometry Study Recruiting NCT02853968
18 International Registry for Patients With Castleman Disease Recruiting NCT02817997
19 Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Withdrawn NCT02805868 Early Phase 1
20 Castleman Disease Collaborative Network Biobank Withdrawn NCT02871050

Search NIH Clinical Center for Multicentric Castleman Disease

Cochrane evidence based reviews: multi-centric castleman's disease

Genetic Tests for Multicentric Castleman Disease

Anatomical Context for Multicentric Castleman Disease

MalaCards organs/tissues related to Multicentric Castleman Disease:

41
Lymph Node, Liver, Testes, Spleen, B Cells, Bone, Bone Marrow

Publications for Multicentric Castleman Disease

Articles related to Multicentric Castleman Disease:

(show top 50) (show all 167)
# Title Authors Year
1
Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. ( 29732477 )
2018
2
The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. ( 29684500 )
2018
3
Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease. ( 29157621 )
2018
4
Plasma Cell Variant Multicentric Castleman Disease and Kaposi's Sarcoma in a Treatment-Naive HIV-Infected Patient. ( 29345958 )
2018
5
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease. ( 29675946 )
2018
6
Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease. ( 29607228 )
2018
7
Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case reporta8c. ( 29701172 )
2018
8
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program. ( 30074630 )
2018
9
Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology. ( 30108026 )
2018
10
ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. ( 30139808 )
2018
11
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. ( 30181172 )
2018
12
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. ( 30203839 )
2018
13
A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease. ( 30404775 )
2018
14
A prospective description of HIV-associated multicentric Castleman disease in Malawi. ( 30442726 )
2018
15
Biologic Agents in the Treatment of Multicentric Castleman Disease. ( 30455994 )
2018
16
Spontaneous middle lobe torsion in a patient with multicentric Castleman disease: A case report. ( 30467976 )
2018
17
Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab. ( 30486744 )
2018
18
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. ( 30487129 )
2018
19
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. ( 30504327 )
2018
20
Late-onset skin involvement on the forehead in multicentric Castleman disease. ( 28244070 )
2017
21
Multicentric Castleman disease: consensus at last? ( 28336727 )
2017
22
EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity. ( 29198143 )
2017
23
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. ( 28087540 )
2017
24
TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. ( 28135567 )
2017
25
Corrigendum: Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. ( 28845155 )
2017
26
Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report. ( 28501028 )
2017
27
Thin-section Computed Tomographic Findings of Multicentric Castleman Disease Changing Over 10 Years. ( 28914746 )
2017
28
Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. ( 28143881 )
2017
29
iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease. ( 28060720 )
2017
30
(18)F-FDG PET/CT in multicentric Castleman disease: a case report. ( 26904580 )
2016
31
A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination. ( 26948831 )
2016
32
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids. ( 26980221 )
2016
33
TAFRO syndrome: An atypical variant of KSHV-negative multicentric Castleman disease. ( 26663467 )
2016
34
Atypical presentation of multicentric Castleman disease in a pediatric patient: pleural and pericardial effusion. ( 26614115 )
2016
35
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. ( 26634298 )
2016
36
Human Herpesvirus Type 8-positive Multicentric Castleman Disease. ( 27133959 )
2016
37
Multicentric Castleman disease: Where are we now? ( 27296355 )
2016
38
Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. ( 27221364 )
2016
39
Unicentric versus Multicentric Castleman Disease. ( 27618317 )
2016
40
Multicentric Castleman Disease With Tubulointerstitial Nephritis Mimicking IgG4-related Disease: Two Case Reports. ( 26598921 )
2016
41
Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. ( 26805758 )
2016
42
Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. ( 27741115 )
2016
43
Bone marrow manifestations in multicentric Castleman disease. ( 26817834 )
2016
44
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. ( 25093377 )
2015
45
Plasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapy. ( 25900626 )
2015
46
Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. ( 26137030 )
2015
47
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. ( 26124203 )
2015
48
Siltuximab for Multicentric Castleman Disease-Letter. ( 26473194 )
2015
49
18F-fluorodeoxyglucose Positron Emission Tomography in Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease: Correlation With Activity, Severity, Inflammatory and Virologic Parameters. ( 25828248 )
2015
50
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. ( 25601959 )
2015

Variations for Multicentric Castleman Disease

Expression for Multicentric Castleman Disease

Search GEO for disease gene expression data for Multicentric Castleman Disease.

Pathways for Multicentric Castleman Disease

Pathways related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.46 ABCB1 IL10 IL21 IL5 IL6
2
Show member pathways
12.24 IL10 IL21 IL5 IL6
3
Show member pathways
12.18 IL10 IL5 IL6
4
Show member pathways
12.03 IL10 IL21 IL5 IL6
5 11.99 BCL6 IL6 PAX5
6
Show member pathways
11.83 BCL6 IL10 IL6
7
Show member pathways
11.78 IL10 IL21 IL6
8 11.7 IL10 IL5 IL6
9 11.67 BCL6 IL10 IL6
10 11.6 IL10 IL21 IL6
11 11.23 BCL6 IL10 IL5
12 11.13 IL10 IL6
13 11.12 IL10 IL6
14 11.07 IL5 IL6
15 10.97 IL10 IL5
16 10.8 CRP IL6
17 10.74 IL10 IL21 IL5 IL6
18 10.69 IL10 IL21 IL5 IL6
19 10.65 BCL6 IL10 IL21 PAX5
20 10.59 IL10 IL5 IL6

GO Terms for Multicentric Castleman Disease

Cellular components related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 CRP F3 IL10 IL21 IL5 IL6
2 extracellular space GO:0005615 9.1 CRP F3 IL10 IL21 IL5 IL6

Biological processes related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.76 IL10 IL21 IL5 IL6
2 regulation of signaling receptor activity GO:0010469 9.73 IL10 IL21 IL5 IL6
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.54 IL10 IL5 IL6
4 acute-phase response GO:0006953 9.49 CRP IL6
5 positive regulation of JAK-STAT cascade GO:0046427 9.48 IL5 IL6
6 positive regulation of immunoglobulin secretion GO:0051024 9.4 IL5 IL6
7 inflammatory response GO:0006954 9.35 BCL6 CRP IL10 IL5 IL6
8 positive regulation of B cell proliferation GO:0030890 9.33 BCL6 IL21 IL5
9 negative regulation of lipid storage GO:0010888 9.32 CRP IL6
10 type 2 immune response GO:0042092 9.26 BCL6 IL10
11 cytokine-mediated signaling pathway GO:0019221 9.02 BCL6 F3 IL10 IL5 IL6

Molecular functions related to Multicentric Castleman Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 IL10 IL5 IL6
2 cytokine activity GO:0005125 8.92 IL10 IL21 IL5 IL6

Sources for Multicentric Castleman Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....